Amitriptyline hydrochloride is under clinical development by AlgoTherapeutix and currently in Phase II for Erythromelalgia. According to GlobalData, Phase II drugs for Erythromelalgia does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Amitriptyline hydrochloride LoA Report. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Likelihood of Approval and Phase Transition Success Rate Model - Amitriptyline Hydrochloride in Erythromelalgia

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Amitriptyline hydrochloride overview

Amitriptyline hydrochloride is under development for the treatment of chemotherapy-induced peripheral neuropathy, erythromelalgia and phantom limb pain. The drug candidate is administered through topical route. It acts by targeting voltage gated sodium channels (Nav1.7, Nav1.8 and Nav1.9).

AlgoTherapeutix overview

AlgoTherapeutix (AlgoTx) is a biotechnology company developing innovative medicines for complex pain, with initial programs focusing on chemotherapy-induced neuropathic pain and erythromelalgia. AlgoTx is headquartered in Paris, Ile-de-France, France.

For a complete picture of Amitriptyline hydrochloride’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 16 July 2024

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.